AZ-23 (C09-1101-506)

AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC 50 s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.In VitroAZ-23 potently and selectivity inhibits Trk phosphorylation in cells. AZ-23 potently inhibits Trk-mediated survival (EC 50 of 2 nM). AZ-23 Inhibits Trk-Dependent Survival in MCF10ATrkA-Δ and TF-1 Cell Lines. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoAZ-23 shows in vivo TrkA kinase inhibition and efficacy in mice following oral administration in a TrkA-driven allograft model and significant tumor growth inhibition in a Trk-expressing xenograft model of neuroblastoma . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:TrkA 2 nM (IC 50 ) TrkB 8 nM (IC 50 ). Specifications and Purity: 98%. Molecular Formula: C17H19ClFN7O. Molecular Weight: 391.83. PubChem CID: 16097523. Isomeric SMILES: C[C@@H](C1=NC=C(C=C1)F)NC2=NC=C(C(=N2)NC3=CC(=NN3)OC(C)C)Cl.